Clinical Trial: Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07631650) titled 'Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients' on May 27.

Brief Summary: Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Head and Neck Disorder Head and Neck Cancer

Intervention: DRUG: Bevonescein (ALM 488) Infusion

Bevonescein is a synthetic peptide of 17 amino acids conjugated to a fluorescein derivative ...